What did the study on edible cannabis with 25 oncology patients really show, what do the ASCO guidelines from 2024 recommend, and what does access to cannabis look like in Poland.
Cannabinoids in neuropathic pain without marketing: a Cochrane review, NeuPSIG guidelines, a study from Hamburg, drug interactions, and Polish prescription rules Rpw.
CBD alone does not cause red eyes, while THC does, and this effect lasts for 2-3 hours. The mechanism, time frames, and which drops help and which harm in the long run.
CBD increases the concentration of escitalopram and sertraline by up to 35%. Brand names from Polish pharmacies, symptoms of serotonin syndrome, and when it is dangerous.
What was really measured in studies on cannabis and the heart, who belongs to the risk group, what symptoms require urgent response, and how CBD alters drug effects.
Psilocybin in psychotherapy: what the NEJM and JAMA Psychiatry studies really showed, what risks it carries, and why it is listed in Poland as I-P.
Acidic CBDA and CBGA limit larval feeding in studies from Cornell University. Evidence, mechanisms, and the legal status in the European Union and Poland.
Does hemp flower improve performance before training? A review of 15 studies, cardiovascular risks, effects on coordination, WADA rules, and the Polish legal status.
How many publications on cannabis were produced in the last decade, what this number includes, how many of them are randomized studies, and how to read these reports.
Adaptogens and cortisol and the HPA axis: what studies on ashwagandha, rhodiola, eleutherococcus, and ginseng really showed. Drug interactions and legal status.
CBD for social phobia: what was measured in three small trials, why therapy and SSRIs remain the first choice, and when anxiety requires same-day help.
CBD oil without marketing: what is really known about absorption, dosing, drug interactions, quality, and the Polish THC threshold. With sources and dates.
Are you over 18 years old?
Book with you
